title: Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
abstract: Serum S-100 protein is widely used as a marker of melanoma and since 5-S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5-S-CD was determined by HPLC. The value of S-100 protein in patients with primary melanoma (0.11m mg/l) and in patients without symptoms (0.15 m mg/l) ranged around the normal level (0.01 0.12 m mg/l). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S-100 values of clinical Stage I (0.11 mg/l) and Stage III (2.91 mg/l) as well as between those of clinical Stage II (0.47 mg/l) and Stage III (2.91 mg/l), respectively. Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III.
authors.affiliation: National Institute of Oncology, Department of Dermatology Ráth György u. 7-9., Budapest, H-1122, Hungary. banfalvi@oncol.hu
authors.forename: T
authors.initials: T
authors.lastname: Bánfalvi
authors.forename: K
authors.initials: K
authors.lastname: Gilde
authors.forename: M
authors.initials: M
authors.lastname: Boldizsár
authors.forename: T
authors.initials: T
authors.lastname: Kremmer
authors.forename: S
authors.initials: S
authors.lastname: Ottó
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D003548:Cysteinyldopa / Q000097:blood*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008198:Lymph Nodes / Q000473:pathology; D008543:Melanins / Q000096:biosynthesis; D008545:Melanoma / Q000097:blood*; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009418:S100 Proteins / Q000097:blood*; D012878:Skin Neoplasms / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D008543:Melanins; D009418:S100 Proteins; D003548:Cysteinyldopa